TGF‐β signaling: A recap of SMAD‐independent and SMAD‐dependent pathways
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Transforming growth factor‐β (TGF‐β) is a proinflammatory cytokine known to control a diverse array of pathological and physiological conditions during normal development and tumorigenesis. TGF‐β‐mediated physiological effects are heterogeneous and vary among different types of cells and environmental conditions. TGF‐β serves as an antiproliferative agent and inhibits tumor development during primary stages of tumor progression; however, during the later stages, it encourages tumor development and mediates metastatic progression and chemoresistance. The fundamental elements of TGF‐β signaling have been divulged more than a decade ago; however, the process by which the signals are relayed from cell surface to nucleus is very complex with additional layers added in tumor cell niches. Although the intricate understanding of TGF‐β‐mediated signaling pathways and their regulation are still evolving, we tried to make an attempt to summarize the TGF‐β‐mediated SMAD‐dependent andSMAD‐independent pathways. This manuscript emphasizes the functions of TGF‐β as a metastatic promoter and tumor suppressor during the later and initial phases of tumor progression respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“TGF‐β is primarily associated with the induction of EMT, a process that primarily occurs during normal development of embryos and is pathologically coupled with the dissemination and invasion of tumors and the development of fibrotic diseases (Lamouille et al., 2014; Moustakas & Heldin, 2012).”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
RHO GTPASES: Biochemistry and Biology
Jaffe, A. B., & Hall, A. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.020604.150721 · Cited by 3,009
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · cited 1×
“The key modules of the pathway, the PI3Ks (phosphatidylinositide‐3‐kinases), Akt and mammalian target of rapamycin (mTOR) are frequently hyperactivated in most cancers (Thorpe et al., 2015; Vanhaesebroeck et al., 2010).”
BackgroundYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., & Hung, M.-C. (2004) · Nature Cell Biology · doi:10.1038/ncb1173 · Cited by 1,581 · cited 1×
“Akt mediates the phosphorylation of GSK3β (glycogen synthase kinase 3β) and hence stabilizes NF‐κB and Snail, a transcription factor involved in EMT, thus promoting Snail‐dependent transcription in EMT (Julien et al., 2007; Zhou et al., 2004).”
BackgroundSmad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription
Zhang, Y., Feng, X.-H., & Derynck, R. (1998) · Nature · doi:10.1038/29814 · Cited by 809 · cited 1×
“In addition, the Erk1/2 substrates, including the members of the AP‐1 family also bind SMADs and act in conjugation with SMADs to control target gene expression (Davies et al., 2005; Hall et al., 2003; Zhang et al., 1998).”
BackgroundSpecificity, versatility, and control of TGF-β family signaling
Derynck, R., & Budi, E. H. (2019) · Science Signaling · doi:10.1126/scisignal.aav5183 · Cited by 785 · cited 1×
“Dysregulation of TGF‐β signaling results in the development of various diseases like cancer and fibrotic diseases and also leads to various developmental defects (Rik Derynck & Budi, 2019).”
BackgroundRegulation of cell polarity and protrusion formation by targeting RhoA for degradation
Wang, H.-R., Zhang, Y., Ozdamar, B., Ogunjimi, A. A., Alexandrova, E., Thomsen, G. H., & Wrana, J. L. (2003) · Science · doi:10.1126/science.1090772 · Cited by 551
Syed, V. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25496 · Cited by 482 · cited 1×
“TGF‐β promotes apoptosis and cell cycle arrest in early‐stage cancers; however, in advanced tumors, it promotes cell motility, invasion, cell stemness, EMT and hence metastasis and tumor progression (Drabsch & ten Dijke, 2012; Jakowlew, 2006; Syed, 2016; Tian et al., 2011; Xie et al., 2018).”
BackgroundRegulation of TGF-β Family Signaling by Inhibitory Smads
Miyazawa, K., & Miyazono, K. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022095 · Cited by 439
Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins
Robertson, I. B., & Rifkin, D. B. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021907 · Cited by 403
Localization and actions of transforming growth factor-β s in the embryonic nervous system
Flanders, K. C., Lüdecke, G., Engels, S., Cissel, D. S., Roberts, A. B., Kondaiah, P., Lafyatis, R., Sporn, M. B., & Unsicker, K. (1991) · Development · doi:10.1242/dev.113.1.183 · Cited by 359
TGF-β signaling in cancer metastasis
Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx123 · Cited by 231
Mitchell, H., Choudhury, A., Pagano, R. E., & Leof, E. B. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-03-0245 · Cited by 215 · cited 1×
“Therefore, the receptors undergo clathrin‐mediated endocytic downregulation after a few rounds of recycling (Mitchell et al., 2004; Vander Ark et al., 2018).”
BackgroundLiu, Y., Liu, H., Meyer, C., Li, J., Nadalin, S., Königsrainer, A., Weng, H., Dooley, S., & ten Dijke, P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478685 · Cited by 181
Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells
Boergermann, J. H., Kopf, J., Yu, P. B., & Knaus, P. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.07.018 · Cited by 175 · cited 2×
“In addition, both branches of TGF‐β signaling, SMAD and non‐SMAD pathways, have been implicated in the activation of Akt (Bakin et al., 2000; Boergermann et al., 2010; Gamell et al., 2008; Ghosh‐Choudhury et al., 2002; Lamouille & Derynck, 2007; Viñals & Pouysségur, 2001).”
BackgroundSmad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling
Tsukamoto, S., Mizuta, T., Fujimoto, M., Ohte, S., Osawa, K., Miyamoto, A., Yoneyama, K., Murata, E., Machiya, A., Jimi, E., et al. (2014) · Scientific Reports · doi:10.1038/srep07596 · Cited by 122 · cited 1×
“…and (iii) the antagonistic or inhibitory SMADs, which includes SMAD6 and 7, which negatively regulate the SMAD‐dependent signaling pathways by either degrading the receptors or competing with R‐SMADs for active heterotetrameric receptor complex binding (Massagué, 1998; Tsukamoto et al., 2014).”
BackgroundEvolution of the TGF-β Signaling Pathway and Its Potential Role in the Ctenophore, Mnemiopsis leidyi
Pang, K., Ryan, J. F., Baxevanis, A. D., & Martindale, M. Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024152 · Cited by 93
Cited by
Postwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
Metadata
- Authors
- Aashaq, S., Batool, A., Mir, S. A., Beigh, M. A., Andrabi, K. I., & Shah, Z. A.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2021-07-19
- Volume
- 237
- Issue
- 1
- Pages
- 59-85
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W3183476852
- Cited by
- 211
- References
- 20
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.